Novartis Won't Raise Chiron Bid
The Swiss drug company was responding to a letter that ValueAct Capital, an investment management firm in San Francisco, sent to Chiron, saying the offer was too low. ValueAct, the owner of about 5% of Chiron's stock, says it will vote against the Novartis offer.
Novartis is seeking to buy the 56% of Chiron's shares that it doesn't own. The company made a $40-a-share bid in September, but Chiron's board rejected the proposal. In late October, Novartis raised the price.
The Federal Trade Commission has approved the transaction. The companies need clearance from the European Union and a majority of Chiron shares, excluding those owned by Novartis.Get Jim Cramer's picks for 2006.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV